In the Philippines, access to comprehensive genomic profiling (CGP), circulating tumor DNA (ctDNA), and cell-free DNA (cfDNA) ...

Biomarker testing has the potential to improve patient outcomes significantly, but its high cost means it's not accessible to everyone.

Cancer treatment has advanced significantly, helping more people live longer, healthier lives. However, some of these life ...

Research by Cancer Research UK found that about 28,400 cancer deaths each year are associated with deprivation.

Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing ...

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

The tool predicts which of two standard front-line chemotherapy options a patient with advanced pancreatic cancer is likely to benefit from.

In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.

Nowadays, targeted therapies remain the gold standard for many patients ... The results of the phase I trial conducted on advanced or metastatic non-small cell lung cancer (NSCLC) patients bearing ...

Although lung cancer has been the leading cause of lung-cancer death globally for decades, there are important temporal and geographical differences in lung-cancer incidence, mortality, and other ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...